Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease
Open accessThe DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
Stargardt disease (STGD1) due to mutations in the large ABCA4 gene is the most common inherited macular degeneration in humans. We have shown that dual adeno-associated viral (AAV) vectors effectively transfer ABCA4 to the retina of Abca4-/- mice. However, they express both lower levels of transgene compared with a single AAV and truncated proteins. To increase productive dual AAV concatemerization, which would overcome these limitations, we have explored the use of either various regions of homology or heterologous inverted terminal repeats (ITR). In addition, we tested the ability of various degradation signals to decrease the expression of truncated proteins. We found the highest levels of transgene expression using regions of homology based on either alkaline phosphatase or the F1 phage (AK). The use of heterologous ITR does not decrease the levels of truncated proteins relative to full-length ABCA4 and impairs AAV vector production. Conversely, the inclusion of the CL1 degradation signal results in the selective degradation of truncated proteins from the 5'-half without affecting full-length protein production. Therefore, we developed dual AAV hybrid ABCA4 vectors including homologous ITR2, the photoreceptor-specific G protein-coupled receptor kinase 1 promoter, the AK region of homology and the CL1 degradation signal. We show that upon subretinal administration these vectors are both safe in pigs and effective in Abca4-/- mice. Our data support the use of improved dual AAV vectors for gene therapy of STGD1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In spite of this, the protein expression levels achievable may be sufficient to slow down or stop disease progression [Trapani 2015, McClements 2019].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as Trapani 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even though others have detected OL reconstitution in RPE cells, but not photoreceptors, this may be due to differences in overlap lengths and sequences (Trapani et al., 2015).”
From Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting (2017) · cites this paper as Trapani et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a general issue of dual/triple AAV vectors is the potential production of aberrant protein products from (i) erroneous reassembly and/or from (ii) the untoward expression of individual split transgenes.”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subretinal administration of AAV2/8 using transsplicing and hybrid vector strategies has shown efficient retinal pigment epithelium and photoreceptor transduction [29,30,101].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When the authors compared three minimal AP HR constructs to the phage F1 HR constructs in HEK293 cells, one of the shortened AP HR vectors (AP1) showed slightly higher expression levels compared with the two other vector systems. 60”
From Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids (2016) · cites this paper as [60]
Experimental — accuracy not yet measured
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationIn Vivo Half-Life of a Protein Is a Function of Its Amino-Terminal Residue
Bachmair, A., Finley, D., & Varshavsky, A. (1986) · Science · doi:10.1126/science.3018930 · Cited by 1,971
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Allikmets, R., Singh, N., Sun, H., Shroyer, N. F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0397-236 · Cited by 1,435 · cited 1×
“Stargardt disease (STGD1; MIM#248200), the most common form of inherited macular degeneration in humans, is caused by mutations in ABCA4 [coding sequence (CDS): 6822 bp], which encodes the photoreceptor (PR)-specific all-trans-retinal transporter (1,2).”
Delori, F. C., Dorey, C. K., Staurenghi, G., Arend, O., Goger, D. G., & Weiter, J. J. (1995) · PubMed · Cited by 948
Weng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881 · cited 1×
“Abca4−/−mice (3), the only STGD1 animalmodel, recapitulate some of the features of the human retinal disease including abnormal lipofuscin accumulation in the RPE.”
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citationSimonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553
Self-citation
Research works printed but not linked: 1
- Sambrook J., Russell D.W. (2001) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, New York, USA.
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-citationAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
Tornabene, P., Trapani, I., Minopoli, R., Centrulo, M., Lupo, M., de Simone, S., Tiberi, P., Dell’Aquila, F., Marrocco, E., Iodice, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4523 · Cited by 192
Self-citationAdeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes.
McClements, M. E., & MacLaren, R. E. (2017) · PubMed Central · Cited by 144
Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids
Chamberlain, K., Riyad, J. M., & Weber, T. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.140 · Cited by 141
Let There Be Light: Gene and Cell Therapy for Blindness
Dalkara, D., Goureau, O., Marazova, K., & Sahel, J.-A. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.147 · Cited by 129
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Self-citationGene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
AAV-mediated CRISPR/cas gene editing of retinal cells in vivo
Hung, S. S. C., Chrysostomou, V., Li, F., Lim, J. K. H., Wang, J.-H., Powell, J. E., Tu, L., Daniszewski, M., Lo, C., Wong, R. C., et al. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19316 · Cited by 125
Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 109
Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration
Molday, R. S., Garces, F. A., Scortecci, J. F., & Molday, L. L. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101036 · Cited by 107
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92
“Other research groups have attempted to reduce unwanted protein production from dual vectors by inclusion of additional genetic sequences in the transgene design.(14) However, our own attempts employed sequence selection of coding regions that carried out-of-frame ATG codons prior to any in-frame ATG codons within 100…”
BackgroundInfluentialBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“An update on dual and triple rAAV vectors can be found in a recent paper by Trapani [214] who successfully applied a dual ABCA4 AAV vector system in Abca4 knockout mice [215,216].”
BackgroundEvaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86
An Overview of the Genetics of ABCA4 Retinopathies, an Evolving Story
Al‐Khuzaei, S., Broadgate, S., Foster, C. R., Shah, M., Yu, J., Downes, S. M., & Halford, S. (2021) · Genes · doi:10.3390/genes12081241 · Cited by 85
Bioengineering strategies for restoring vision
Cehajic-Kapetanovic, J., Singh, M. S., Zrenner, E., & MacLaren, R. E. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00836-4 · Cited by 79
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
Self-citationAdeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Trapani, I. (2019) · Genes · doi:10.3390/genes10040287 · Cited by 73
“A number of studies have indeed shown the ability of these strategies to reconstitute large transgenes in the retina [20,21,26,35,36] at levels which were higher compared to the other dual AAV strategies tested side by side [20,21,26], and which resulted in improvement of the retinal phenotype of animal models of IRDs…”
BackgroundResultInfluentialSelf-citationHolmgaard, A., Askou, A. L., Benckendorff, J. N. E., Thomsen, E. A., Cai, Y., Bek, T., Mikkelsen, J. G., & Corydon, T. J. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.08.016 · Cited by 73
AAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 74
Novel therapeutics for Stargardt disease
Lu, L. J., Liu, J., & Adelman, R. A. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3619-8 · Cited by 72
Design of AAV Vectors for Delivery of Large or Multiple Transgenes
Patel, A., Zhao, J., Duan, D., & Lai, Y. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_2 · Cited by 73
Xue, K., & MacLaren, R. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1804853 · Cited by 69
In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies
Yanik, M., Müller, B., Song, F., Gall, J., Wagner, F., Wende, W., Lorenz, B., & Stieger, K. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.001 · Cited by 66
Stargardt disease and progress in therapeutic strategies
Huang, D., Jeffery, R. C. H., Aung-Htut, M. T., McLenachan, S., Fletcher, S., Wilton, S. D., & Chen, F. K. (2021) · Ophthalmic Genetics · doi:10.1080/13816810.2021.1966053 · Cited by 58
Marrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
“Including degradation sequences in the 5′-half-containing vector has successfully minimized the untoward generation of truncated proteins [30], achieving improved features that may prove beneficial for the clinical application of dual AAVs to target this disease.”
BackgroundInfluentialNon-viral Gene Therapy for Stargardt Disease with ECO/pRHO-ABCA4 Self-Assembled Nanoparticles
Sun, D., Schur, R. M., Sears, A. E., Gao, S.-Q., Vaidya, A., Sun, W., Maeda, A., Kern, T., Palczewski, K., & Lu, Z.-R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.010 · Cited by 54
Dual and triple AAV delivery of large therapeutic gene sequences into the inner ear
Akil, O. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107912 · Cited by 52
ADIPOR1 is essential for vision and its RPE expression is lost in the Mfrprd6 mouse
Sluch, V. M., Banks, A., Li, H., Crowley, M. A., Davis, V., Xiang, C., Yang, J., Demirs, J. T., Vrouvlianis, J., Leehy, B. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32579-9 · Cited by 51
Therapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
Off-Target Expression of Cre-Dependent Adeno-Associated Viruses in Wild-Type C57BL/6J Mice
Botterill, J. J., Khlaifia, A., Walters, B. J., Brimble, M. A., Scharfman, H. E., & Arruda-Carvalho, M. (2021) · eNeuro · doi:10.1523/eneuro.0363-21.2021 · Cited by 48
Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
Barbon, E., Kawecki, C., Marmier, S., Sakkal, A., Collaud, F., Charles, S., Ronzitti, G., Casari, C., Christophe, O. D., Denis, C. V., et al. (2021) · Gene Therapy · doi:10.1038/s41434-020-00218-6 · Cited by 48
Gene-agnostic therapeutic approaches for inherited retinal degenerations
John, M. C., Quinn, J., Hu, M. L., Cehajic‐Kapetanovic, J., & Xue, K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1068185 · Cited by 43
Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression
Vidal, P., Pagliarani, S., Colella, P., Verdera, H. C., Jauze, L., Gjorgjieva, M., Puzzo, F., Marmier, S., Collaud, F., Sola, M. S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.019 · Cited by 42
Self-citationAdeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
“Even if the reconstitution efficiency is low, phenotypic improvement in disease models have been reported in previous studies.(52,54,55) Furthermore, some genes involved in genetic disease are still larger than dual-AAVs capacity.”
BackgroundResultRetinal cadherins and the retinal cadherinopathies: Current concepts and future directions
Yusuf, I. H., Garrett, A. M., MacLaren, R. E., & Issa, P. C. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101038 · Cited by 40
Dual-AAV delivery of large gene sequences to the inner ear
Reisinger, E. (2020) · Hearing Research · doi:10.1016/j.heares.2019.107857 · Cited by 37
Effective gene therapy of Stargardt disease with PEG-ECO/pGRK1-ABCA4-S/MAR nanoparticles
Sun, D., Sun, W., Gao, S., Lehrer, J., Naderi, A., Wei, C., Lee, S.-J., Schilb, A. L., Scheidt, J. H., Hall, R. C. W., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.026 · Cited by 35
Beier, K. T. (2022) · eLife · doi:10.7554/elife.76886 · Cited by 35
Revolution in Gene Medicine Therapy and Genome Surgery
Jiang, D. J., Xu, C. L., & Tsang, S. H. (2018) · Genes · doi:10.3390/genes9120575 · Cited by 35
Large gene delivery to the retina with AAV vectors: are we there yet?
Trapani, I., Tornabene, P., & Auricchio, A. (2020) · Gene Therapy · doi:10.1038/s41434-020-0174-4 · Cited by 32
Self-citationTornabene, P., Trapani, I., Centrulo, M., Marrocco, E., Minopoli, R., Lupo, M., Iodice, C., Gesualdo, C., Simonelli, F., Surace, E. M., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.004 · Cited by 25
Self-citationZhang, C., Zhou, X., Yao, T., Tian, Z., & Zhou, D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700374 · Cited by 25
Ocular gene therapy for choroideremia: clinical trials and future perspectives
Xue, K., & MacLaren, R. E. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1475232 · Cited by 24
Chuang, K., Ma, F., & Priore, L. V. D. (2017) · PubMed Central · Cited by 24
Ferreira, M. V., Fernandes, S., Almeida, A. I., Neto, S., Mendes, J. P., Silva, R. J. S., Peixoto, C., & Coroadinha, A. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310524 · Cited by 22
Split AAV8 Mediated ABCA4 Expression for Gene Therapy of Mouse Stargardt Disease (STGD1)
Li, R., Jing, Q., She, K., Wang, Q., Jin, X., Zhao, Q., Su, J., Song, L., Fu, J., Wu, X., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.017 · Cited by 21
“45 The overlapping region between the upstream transgene and downstream transgene was also demonstrated to signifi-cantly influence the levels of truncated ABCA4.”
Gene therapy approaches for prevention of retinal degeneration in Usher syndrome
Williams, D. S., Chadha, A., Hazim, R. A., & Gibbs, D. (2017) · Gene Therapy · doi:10.1038/gt.2016.81 · Cited by 21
Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy
Albini, S., Palmieri, L., Dubois, A., Bourg, N., Lostal, W., & Richard, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411421 · Cited by 21
Delivering large genes using adeno-associated virus and the CRE-lox DNA recombination system
Datta, P., Rhee, K.-D., Staudt, R. J., Thompson, J. M., Hsu, Y., Hassan, S., Drack, A. V., & Seo, S. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae144 · Cited by 20
Dual AAV vectors for efficient delivery of large transgenes
Mittas, D. M., Riedmayr, L. M., Gavrilov, Z., Weber, V. J., Otify, D. Y., Mehlfeld, V., Szalontai, B., Ucambarlic, E., Gandor, C. L. A., Heigl, T., et al. (2025) · Nature Protocols · doi:10.1038/s41596-025-01243-8 · Cited by 21
Ferla, R., Pugni, E., Lupo, M., Tiberi, P., Fioretto, F., Perota, A., Duchi, R., Lagutina, I., Gesualdo, C., Rossi, S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt9354 · Cited by 19
Self-citationShamshad, A., Kang, C., Jenny, L. A., Persad‐Paisley, E. M., & Tsang, S. H. (2023) · Vision Research · doi:10.1016/j.visres.2023.108258 · Cited by 18
Wu, F., He, W., Xiao, Y., Wu, Q., Zhang, Q., Zhang, T., Xu, L., & Pang, X. (2025) · Advanced Science · doi:10.1002/advs.202408397 · Cited by 17
Chen, S., Zhang, W., Sun, C., Song, M., Liu, S., Xu, M., Zhang, X., Liu, L., & Liu, C. (2020) · Advanced Science · doi:10.1002/advs.202000542 · Cited by 17
The role of voltage-gated ion channels in visual function and disease in mammalian photoreceptors
Rashwan, R., Hunt, D. M., & Carvalho, L. S. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02595-2 · Cited by 17
Developing New Vectors for Retinal Gene Therapy
Zin, E. A., Öztürk, B. E., Dalkara, D., & Byrne, L. C. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041291 · Cited by 14
Piotter, E., McClements, M. E., & MacLaren, R. E. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.814131 · Cited by 12
Chen, S., Zhang, W., Sun, C., Song, M., Liu, S., Xu, M., Zhang, X., Liu, L., & Liu, C. (2021) · Advanced Science · doi:10.1002/advs.202101789 · Cited by 12
Genetic engineering and the eye
Murphy, R., & Martin, K. R. G. (2024) · Eye · doi:10.1038/s41433-024-03441-2 · Cited by 9
Corradi, Z., Salameh, M., Khan, M., Héon, E., Mishra, K., Hitti‐Malin, R. J., AlSwaiti, Y., Aslanian, A., Banin, E., Brooks, B. P., et al. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.4.20 · Cited by 9
Clinical gene therapy restores hearing: a paradigm shift
Han, S., Chen, Z., Wang, D., Jiang, L., Fan, X., Zhong, J., Cui, C., Chen, Y., lv, J., Zhang, J., et al. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.07.007 · Cited by 8
Galli, A., Iaia, I., Milella, M. S., Cipriani, F., Latta, V. D., Giacca, M., Zentilin, L., & Cervelli, T. (2021) · Molecular Biotechnology · doi:10.1007/s12033-020-00294-4 · Cited by 7
Gene Therapy for Inherited Retinopathies: Update on Development Progress
Sun, S. Y., & Montezuma, S. R. (2018) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126418783934 · Cited by 6
Zheng, H., Yuan, J., Xiao, X., Ye, L., & Chen, C. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220216101539 · Cited by 6
Brigande, J. V. (2017) · Nature Biotechnology · doi:10.1038/nbt.3815 · Cited by 6
Correcting visual loss by genetics and prosthetics
Xue, K., & MacLaren, R. E. (2020) · Current Opinion in Physiology · doi:10.1016/j.cophys.2020.03.003 · Cited by 5
“In spite of this, the protein expression levels achievable may be sufficient to slow down or stop disease progression [Trapani 2015, McClements 2019].”
BackgroundGene therapy shines light on congenital stationary night blindness for future cures
Zhang, Y., Lin, S., Yu, L., Lin, X. Y., Qu, S., Ye, Q., Yu, M., Chen, W., & Wu, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06392-8 · Cited by 5
Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
Cagin, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_15 · Cited by 5
Gene therapy for inherited retinal diseases
Dhooge, P. P. A., Valkenburg, D., & Hoyng, C. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00017-4 · Cited by 5
Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease
Burgess, F. R., Hall, H. N., & Megaw, R. D. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000545 · Cited by 4
Liu, F., Li, Q., Su, J., Fu, J., Wu, X., Xu, Q., Ren, C., Jin, X., Song, L., Lu, F., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.12.29 · Cited by 4
Al‐Moyed, H. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7430 · Cited by 3
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease
Zhu, S., Zhang, J., Jiang, X., Peng, C., Liu, H., & Qian, F. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115773 · Cited by 3
New possibilities in the treatment of Stargardt disease
Zhorzholadze, N. V., Sheremet, N. L., Tanas, A. S., & Strelnikov, V. V. (2020) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2020136042333 · Cited by 3
Brillante, S., Volpe, M., Diana, A., Negueruela, S., Molinari, M., Saurino, R., Cipollaro, E., Polishchuk, E., Tenderini, E., Damiano, C., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504764123 · Cited by 2
Self-citationDuarte, F. T., & Arsenijévic, Y. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101424 · Cited by 2
孔令芸, Xin, C., Cheng, M., Ma, S., Zheng, Z., Chen, J., & Zhou, X. (2026) · Eye Discovery · doi:10.1016/j.edisc.2026.100040 · Cited by 2
Virus Vectors for Optogenetic Prosthetization of the Retina
Rotov, A. Y., Nikolaeva, D. A., Astakhova, L. A., & Firsov, M. L. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-00911-4 · Cited by 2
Boye, S. L., Durham, T. A., Laster, A., Gelfman, C. M., & Sahel, J. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.2.2 · Cited by 2
AAV-mediated CRISPR/Cas gene editing of retinal cells in vivoPreprint
Hung, S. S., Chrysostomou, V., Li, F., Lim, J. K., Wang, J.-H., Powell, J. E., Tu, L., Daniszewski, M., Lo, C., Wong, R. C., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/039156 · Cited by 1
Punzo, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00019-8 · Cited by 1
Peek, J. L., Rosales, A., Qi, J., Feleke, L., Menshikh, A., Welch, R., Woodard, L. E., Asokan, A., & Wilson, M. H. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201736 · Cited by 1
Camp, D. A., Gemayel, M. C., & Ciulla, T. A. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1898373 · Cited by 1
Molecular insights into PCARE-associated retinal disease
Serrano, J. C. C. (2018) · Radboud Repository (Radboud University) · Cited by 1
Update on the Management of ABCA4 Retinopathy (Stargardt Disease)
Parameswarappa, D. C., Ratra, D., Chattannavar, G., & Padhy, S. K. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01407-z
Développement d'un traitement de thérapie génique pour la glycogénose de type III
Vidal, P. (2018) · theses.fr (ABES) · doi:10.70675/5e174471z66d8z44dbza2edz3adc480b1f41
Oloruntimehin, E. S., & Malogolovkin, A. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135668
Stargardt Disease ( ABCA4 -Associated Retinopathies)
Utz, V. M., & Traboulsi, E. I. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0037
Stargardt Disease. Literature review
Zhazybaev, R. S., & Zhirov, A. L. (2026) · Ophthalmology in Russia · doi:10.18008/1816-5095-2026-1-7-13
Esposito, F., Padmanabhan, A., Rhiel, M., Lupo, M., Marrocco, E., Auricchio, S., Cundin, X. B., Pellecchia, S., Cornu, T. I., Andrieux, G., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103047
Self-citationHuang, Q., Yang, D., Zhou, X., Li, G., Liu, W., Fan, X., Yuan, F., & Chang, X. (2026) · Nature Communications · doi:10.1038/s41467-026-75912-x
Retargeting AAV Vectors via Cell-Specific Receptor Binding
Meng, N. (2025) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00036221
Принципы использования рекомбинантных аденоассоциированных вирусов в исследованиях и терапии
С.А., М., & Д.А., Л. (2024) · Письма в Вавиловский журнал генетики и селекции · doi:10.18699/letvjgb-2024-10-24
Antioxidant Strategies for Inherited Retinal Degenerations in the Era of Gene Therapy
Yang, Y., Chen, Q., Zeng, J., Liang, L., Tao, Z., She, K., Ren, C., & Lu, F. (2026) · Antioxidants · doi:10.3390/antiox15101229
Metadata
- Authors
- Trapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., Giunti, M., Bacci, M. L., Polishchuk, R. S., & Auricchio, A.
- Affiliations
- Telethon Institute Of Genetics And Medicine (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Bologna (IT)
- Federico II University Hospital (IT)
- Corresponding author
- Auricchio, Alberto
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-29
- Volume
- 24
- Issue
- 23
- Pages
- 6811-6825
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC4634381
- OpenAlex
- W2172376325
- Cited by
- 94
- References
- 72
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 2 · 2023: 9 · 2022: 9 · 2021: 13 · 2020: 10 · 2019: 8 · 2018: 9 · 2017: 11 · 2016: 6
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Human Molecular Genetics (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- European Research Council/ERC (282085)
- Italian Telethon Foundation (TGM11MT1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Stargardt disease, ABCA4, adeno-associated virus gene therapy, inverted terminal repeats, degradation signals, subretinal gene delivery
- MeSH terms
- Stargardt Disease, Dependovirus, Animals, Disease Models, Animal, Female, Genetic Vectors, Humans, Macular Degeneration, Retina, Swine, Genetic Therapy, ATP-Binding Cassette Transporters, Transgenes, Terminal Repeat Sequences, Mice, HEK293 Cells, Administration, Ophthalmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.